Skip to content
  • Home
  • About
    • Executive Management
    • Investors
    • Board of Directors
    • Scientific Advisory Boards
  • Media
  • Pipeline
    • Central Nervous System
    • Vaccines
  • Careers
  • Contact Us
  • Patient Info
  • Provider Info
  • Latest News

Media

 

News

Nuron Biotech Inks Vaccine License with Mitsubishi Tanabe – Jan 13, 2012

 

Press Release

Nuron Biotech Licenses HibTITER® Vaccine to Mitsubishi Tanabe Pharma Corporation for Japanese Market – Jan 13, 2012

Nuron Biotech Initiates Phase 3 Study of Proprietary Recombinant Human Interferon beta-1b in Relapsing Remitting Multiple Sclerosis – Nov 1, 2011

Nuron Biotech Won the “Life Science Award” by the Philadelphia Business Journal – Oct 6, 2011

Dr. Shankar Musunuri’s Interview with the Executive Leaders Radio – Aug 26, 2011

Nuron Biotech to Develop Long-acting Version of Proprietary Recombinant Human Interferon Beta-1b Utilizing TheraPEG Pegylation Technology – May 26, 2011

Nuron Acquires Assets Related to HibTITER® Conjugate Vaccine from Wyeth (a wholly owned subsidiary of Pfizer) – Apr 6, 2011

Nuron Biotech Selects the Merck BioManufacturing Network as Manufacturing Supplier for Next Generation Interferon Beta Pivotal Study for Multiple Sclerosis – Feb 10, 2011

Catalent Announces Partnership with Nuron Biotech to Provide Sterile Delivery and Supply of MS Treatment in Phase 3 Clinical Study – Jan 31, 2011

BaroFold Licenses BaroFeron to Nuron Biotech – May 17, 2010

© 2009 Nuron Biotech